Aurobindo Pharma arm gets USFDA Approval for Everolimus Tablets

Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, of Novartis Pharmaceuticals Corp.

This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27.

The approved product has an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT

At 1.42 pm, Aurobindo Pharma was trading at Rs. 1,224.30, up by 0.85%, with a volume of 2.14 lakh shares on the BSE.